The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

Part of paid clinical trials in Buffalo, New York.

Sponsor
State University of New York at Buffalo
Study ID
NCT06128915
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Aging

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • vaccine — OTHER
    Vaccination against 20 serotypes of S. pneumoniae

Study Details

This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.

Key Dates

Start date
Jan 8, 2024
Status verified
Apr 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Vaccination with Prevnar.
    Intramuscular vaccination with Prevnar 20

Primary Outcome Measure

Pneumococcal Opsonophagocytic Killing Activity (OPH) by neutrophils from young versus old donors at 1 week and 1 month after vaccination [ Time Frame: 1 month ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University at BuffaloBuffaloNew York14203
Catherine Wrona

Find similar trials in Buffalo, NY

By research site
University at Buffalo· Buffalo, NY

Related Studies